A. Fisher

Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.

G. Pairaudeau, A. Bailey, E. Cadogan, 2011, Bioorganic & medicinal chemistry letters.

Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.

G. Pairaudeau, A. Bailey, E. Cadogan, 2011, Bioorganic & medicinal chemistry letters.

Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.

G. Pairaudeau, A. Bailey, E. Cadogan, 2014, ACS medicinal chemistry letters.

The discovery of AZD 3199 A new inhaled ultra-long acting 2 receptor agonist with rapid onset of action

David, A. Bailey, E. Cadogan, 2014 .

Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.

U. Schopfer, S. Bevan, R. Portmann, 2007, Journal of medicinal chemistry.

Lead optimisation of pyrazoles as novel FPR1 antagonists.

M. Wenlock, Bryan E. Roberts, Tony R Cook, 2012, Bioorganic & medicinal chemistry letters.

A New Convenient Synthesis of 1-(3-Hydroxy-4-Methoxyphenyl)Ethane-1,2-Diol (iso-Mhpg) and its Enantiomers

F. Kerrigan, A. Fisher, 1998 .